Johnson & Johnson $JNJ Shares Acquired by Autumn Glory Partners LLC

Key Points

• Autumn Glory Partners LLC increased its stake in Johnson & Johnson by 6.9% during Q2, holding 23,835 shares valued at approximately $3.64 million, making it the firm's 12th largest position.
• Executive VP Jennifer L. Taubert sold over 56,000 shares of J&J stock for more than $10 million, reducing her position by 24.08%.
• Johnson & Johnson reported a Q2 EPS of $2.77, exceeding estimates, with revenues at $23.74 billion—up 5.8% year-over-year.

Autumn Glory Partners LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 6.9% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,835 shares of the company's stock after purchasing an additional 1,548 shares during the period. Johnson & Johnson makes up about 1.7% of Autumn Glory Partners LLC's holdings, making the stock its 12th biggest position. Autumn Glory Partners LLC's holdings in Johnson & Johnson were worth $3,641,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of JNJ. Highline Wealth Partners LLC raised its position in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after buying an additional 86 shares during the period. Stone House Investment Management LLC acquired a new position in Johnson & Johnson during the first quarter valued at $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson during the first quarter valued at $48,000. von Borstel & Associates Inc. acquired a new position in Johnson & Johnson during the first quarter valued at $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in Johnson & Johnson during the first quarter valued at $52,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Performance

JNJ opened at $188.95 on Wednesday. The company has a market cap of $455.06 billion, a PE ratio of 20.21, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. The stock has a 50-day moving average of $177.04 and a 200-day moving average of $163.18. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $189.92. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm's revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's payout ratio is currently 55.61%.

Wall Street Analyst Weigh In

Several research firms recently weighed in on JNJ. JPMorgan Chase & Co. upped their price target on Johnson & Johnson from $185.00 to $200.00 and gave the company a "neutral" rating in a research report on Tuesday, September 16th. Erste Group Bank raised Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Sanford C. Bernstein boosted their target price on Johnson & Johnson from $172.00 to $193.00 and gave the company a "market perform" rating in a research note on Monday. The Goldman Sachs Group boosted their target price on Johnson & Johnson from $185.00 to $186.00 and gave the company a "buy" rating in a research note on Friday, September 19th. Finally, Guggenheim upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their target price for the company from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have issued a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $189.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.